Analysts predict that Sorrento Therapeutics Inc (NASDAQ:SRNE) will announce ($0.26) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Sorrento Therapeutics’ earnings. Sorrento Therapeutics posted earnings of ($0.44) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 40.9%. The firm is expected to report its next earnings results on Tuesday, March 20th.
On average, analysts expect that Sorrento Therapeutics will report full-year earnings of ($0.39) per share for the current year. For the next fiscal year, analysts expect that the business will report earnings of ($0.65) per share, with EPS estimates ranging from ($0.83) to ($0.46). Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that cover Sorrento Therapeutics.
SRNE has been the topic of several analyst reports. Oppenheimer set a $6.00 price objective on Sorrento Therapeutics and gave the stock a “buy” rating in a report on Wednesday, November 15th. BidaskClub upgraded Sorrento Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, December 20th. ValuEngine upgraded Sorrento Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 3rd. Finally, HC Wainwright restated a “buy” rating and set a $30.00 price objective (up previously from $20.00) on shares of Sorrento Therapeutics in a report on Tuesday, January 16th. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $13.67.
A number of institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp boosted its holdings in Sorrento Therapeutics by 62.8% in the fourth quarter. Bank of New York Mellon Corp now owns 54,598 shares of the biopharmaceutical company’s stock valued at $207,000 after acquiring an additional 21,064 shares during the last quarter. Monashee Investment Management LLC acquired a new position in Sorrento Therapeutics in the fourth quarter valued at $119,000. Alambic Investment Management L.P. acquired a new position in Sorrento Therapeutics in the fourth quarter valued at $151,000. Dimensional Fund Advisors LP boosted its holdings in Sorrento Therapeutics by 408.4% in the second quarter. Dimensional Fund Advisors LP now owns 51,889 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 41,683 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in Sorrento Therapeutics by 139.0% in the third quarter. JPMorgan Chase & Co. now owns 76,169 shares of the biopharmaceutical company’s stock valued at $129,000 after acquiring an additional 44,294 shares during the last quarter. Hedge funds and other institutional investors own 11.93% of the company’s stock.
Shares of Sorrento Therapeutics (NASDAQ SRNE) opened at $6.80 on Friday. Sorrento Therapeutics has a fifty-two week low of $1.50 and a fifty-two week high of $8.25. The company has a current ratio of 0.54, a quick ratio of 0.54 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $539.39, a price-to-earnings ratio of -16.19 and a beta of 1.94.
TRADEMARK VIOLATION WARNING: This piece was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/11/sorrento-therapeutics-inc-srne-expected-to-post-earnings-of-0-26-per-share.html.
Sorrento Therapeutics Company Profile
Sorrento Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.